Key result
Ginsenosides demonstrate potential as a therapeutic strategy for fibrosis-related human diseases by suppressing chronic inflammatory responses, collagen deposition, and myofibroblast activation.
Why the study?
Tissue fibrosis is a pathological feature of chronic illnesses leading to organ failure, and effective antifibrotic therapies remain a significant unmet clinical need.
Do ginsenosides attenuate fibrosis in animal models of fibrosis-related human diseases?
Do ginsenosides attenuate fibrosis in animal models of fibrosis-related human diseases?
Ginsenosides show potential as antifibrotic agents by targeting multiple pathways in preclinical models of fibrosis.
Hypothesis-generating for antifibrotic therapy; clinical trials needed to confirm human efficacy.
Tissue fibrosis is an eventual pathologic change of numerous chronic illnesses, which is characterized by resident fibroblasts differentiation into myofibroblasts during inflammation, coupled with excessive extracellular matrix deposition in tissues, ultimately leading to failure of normal organ function. Now, there are many mechanistic insights into the pathogenesis of tissue fibrosis, which facilitate the discovery of effective antifibrotic drugs. Moreover, many chronic diseases remain a significant clinical unmet need. For the past five years, many research works have undoubtedly addressed the functional dependency of ginsenosides in different types of fibrosis and the successful remission in various animal models treated with ginsenosides. Caveolin-1, interleukin, thrombospondin-1 (TSP-1), liver X receptors (LXRs), Nrf2, microRNA-27b, PPARδ-STAT3, liver kinase B1 (LKB1)-AMPK, and TGF-β1/Smads are potential therapy targeting using ginsenosides. Ginsenosides can play a targeting role and suppress chronic inflammatory response, collagen deposition, and epithelial-mesenchymal transition (EMT), as well as myofibroblast activation to attenuate fibrosis. In this report, our aim was to focus on the therapeutic prospects of ginsenosides in fibrosis-related human diseases making use of results acquired from various animal models. These findings should provide important therapeutic clues and strategies for the exploration of new drugs for fibrosis treatment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted a review in Fibrosis-associated human diseases. Ginsenosides was evaluated. Ginsenosides demonstrate potential as a therapeutic strategy for fibrosis-related human diseases by suppressing chronic inflammatory responses, collagen deposition, and myofibroblast activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: